Institute for Molecular Cardiovascular Research, RWTH Aachen University, Aachen, Germany.
Circulation. 2010 Jan 19;121(2):315-24. doi: 10.1161/CIRCULATIONAHA.109.862771. Epub 2010 Jan 4.
Recent work has revealed an essential involvement of soluble CD40 ligand (sCD40L) in inflammation and atherosclerosis. We investigated whether sCD40L functionally affects peripheral blood-derived angiogenic early outgrowth cells (EOCs) and neointimal remodeling after arterial injury.
Besides myeloid and endothelial markers, cultured human EOCs strongly expressed CD40 mRNA and protein. EOC adhesion to fibronectin, fibrinogen, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 under flow conditions, as well as their transmigration toward stromal cell-derived factor-1alpha, was dose-dependently reduced after preincubation with recombinant human sCD40L for 24 hours. Integrin expression was unaffected by sCD40L, implying that integrin adhesiveness was attenuated. Surface-immobilized CD40L supported much lower adhesion of EOCs than fibronectin. Treatment of EOCs with sCD40L increased superoxide anion production and decreased viability and proliferation. Notably, CD40(-/-) mice displayed reduced neointima and improved re-endothelialization after carotid wire injury compared with wild-type mice, and therapeutic infusion of control EOCs but not EOCs pretreated with sCD40L attenuated neointimal growth after wire injury in nude mice. Furthermore, neointimal growth was more markedly diminished by infusion of spleen-derived CD40(-/-) mouse EOCs than by that of wild-type EOCs. Preincubation of wild-type EOCs but not CD40(-/-) EOCs with sCD40L before their infusion markedly aggravated neointimal formation. Treatment with sCD40L attenuated luminal incorporation of EOCs and accelerated neointimal progression.
Endothelial dysfunction due to persistently elevated plasma levels of sCD40L may be attributable to an impairment of EOC function. Hence, in the context of arterial injury, therapeutic blockade of sCD40L may provide a novel strategy for accelerating endothelial regeneration and attenuating neointimal remodeling.
最近的研究表明,可溶性 CD40 配体(sCD40L)在炎症和动脉粥样硬化中起着重要作用。我们研究了 sCD40L 是否会对动脉损伤后的外周血源性血管生成早期外生细胞(EOC)和新生内膜重塑产生功能影响。
除了髓样细胞和内皮细胞标志物外,培养的人 EOC 强烈表达 CD40 mRNA 和蛋白。在流动条件下,EOC 对纤维连接蛋白、纤维蛋白原、细胞间黏附分子-1 和血管细胞黏附分子-1 的黏附,以及它们向基质细胞衍生因子-1α的迁移,在预先用重组人 sCD40L 孵育 24 小时后,呈剂量依赖性降低。sCD40L 对整合素表达没有影响,表明整合素黏附性降低。表面固定的 CD40L 支持 EOC 的黏附性远低于纤维连接蛋白。sCD40L 处理 EOC 会增加超氧阴离子的产生,降低细胞活力和增殖。值得注意的是,与野生型小鼠相比,CD40(-/-) 小鼠在颈动脉线损伤后表现出新生内膜减少和再内皮化改善,而用对照 EOC 治疗而不是用 sCD40L 预处理的 EOC 治疗可减轻裸鼠线损伤后的新生内膜生长。此外,输注脾源性 CD40(-/-) 小鼠 EOC 比输注野生型 EOC 更显著地减少新生内膜生长。在输注野生型 EOC 之前用 sCD40L 预孵育,但不在 CD40(-/-) EOC 中预孵育,可显著加重新生内膜的形成。sCD40L 治疗可减弱 EOC 管腔的整合,并加速新生内膜的进展。
由于血浆中 sCD40L 水平持续升高而导致的内皮功能障碍可能归因于 EOC 功能受损。因此,在动脉损伤的情况下,sCD40L 的治疗性阻断可能为加速内皮再生和减轻新生内膜重塑提供一种新策略。